83 FR 17668 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 78 (April 23, 2018)

Page Range		17668-17668
FR Document		2018-08364

Federal Register, Volume 83 Issue 78 (Monday, April 23, 2018)

[Federal Register Volume 83, Number 78 (Monday, April 23, 2018)]
[Notices]
[Page 17668]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-08364]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; SEP II for NIH Pathway to Independence Award (K99/
R00).
    Date: April 26, 2018.
    Time: 9:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive 
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; BRAIN Initiative: Tools to Target, Identify and 
Characterize Non-Neuronal Cells in the Brain (R01).
    Date: May 11, 2018.
    Time: 11:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research. National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 
301-827-5840, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Development of Medications to Prevent and Treat 
Opioid Use Disorders and Overdose (UG3/UH3 (Clinical Trials 
Optional).
    Date: May 16, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott Hotel & Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: April 17, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-08364 Filed 4-20-18; 8:45 am]
BILLING CODE 4140-01-P

17668 Federal Register / Vol. 83, No. 78 / Monday, April 23, 2018 / Notices

DEPARTMENT OF HEALTH AND Dated: April 16, 2018. Drug Abuse, NIH, DHHS, 6001 Executive
HUMAN SERVICES Sylvia L. Neal, Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
Program Analyst, Office of Federal Advisory
National Institutes of Health julia.berzhanskaya@nih.gov.
Committee Policy.
Name of Committee: National Institute on
[FR Doc. 2018–08363 Filed 4–20–18; 8:45 am]
National Institute of Arthritis and Drug Abuse Special Emphasis Panel;
BILLING CODE 4140–01–P Development of Medications to Prevent and
Musculoskeletal and Skin Diseases;
Treat Opioid Use Disorders and Overdose
Notice of Closed Meeting (UG3/UH3 (Clinical Trials Optional).
DEPARTMENT OF HEALTH AND Date: May 16, 2018.
Pursuant to section 10(d) of the HUMAN SERVICES Time: 8:00 a.m. to 5:00 p.m.
Federal Advisory Committee Act, as Agenda: To review and evaluate grant
amended, notice is hereby given of a National Institutes of Health applications.
meeting of the Board of Scientific Place: Bethesda North Marriott Hotel &
Counselors, NIAMS. National Institute on Drug Abuse; Conference Center, 5701 Marinelli Road,
Notice of Closed Meetings Bethesda, MD 20852.
The meeting will be closed to the Contact Person: Ivan K. Navarro, Ph.D.,
public as indicated below in accordance Pursuant to section 10(d) of the Scientific Review Officer, Office of
with the provisions set forth in section Federal Advisory Committee Act, as Extramural Policy and Review, Division of
552b(c)(6), Title 5 U.S.C., as amended amended, notice is hereby given of the Extramural Research, National Institute on
for the review, discussion, and following meetings. Drug Abuse, NIH, DHHS, 6001 Executive
The meetings will be closed to the Boulevard, Room 4242, MSC 9550, Bethesda,
evaluation of individual intramural
MD 20892, 301–827–5833, ivan.navarro@
programs and projects conducted by the public in accordance with the nih.gov.
National Institute of Arthritis and provisions set forth in sections
(Catalogue of Federal Domestic Assistance
Musculoskeletal and Skin Diseases, 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Program Nos.: 93.279, Drug Abuse and
including consideration of personnel as amended. The grant applications and Addiction Research Programs, National
qualifications and performance, and the the discussions could disclose Institutes of Health, HHS)
competence of individual investigators, confidential trade secrets or commercial Dated: April 17, 2018.
the disclosure of which would property such as patentable material,
Natasha M. Copeland,
constitute a clearly unwarranted and personal information concerning
Program Analyst, Office of Federal Advisory
invasion of personal privacy. individuals associated with the grant Committee Policy.
Name of Committee: Board of Scientific applications, the disclosure of which
[FR Doc. 2018–08364 Filed 4–20–18; 8:45 am]
Counselors, NIAMS. would constitute a clearly unwarranted
BILLING CODE 4140–01–P
Date: May 22–23, 2018. invasion of personal privacy.
Time: May 22, 2018, 6:00 p.m. to 8:00 p.m. Name of Committee: National Institute on
Agenda: Welcome and program Drug Abuse Special Emphasis Panel; SEP II DEPARTMENT OF HEALTH AND
presentations. for NIH Pathway to Independence Award HUMAN SERVICES
Place: National Institutes of Health, (K99/R00).
Building 31, Room: 4C32, 31 Center Drive, Date: April 26, 2018.
National Institutes of Health
Bethesda, MD 20892. Time: 9:00 a.m. to 6:00 p.m.
Time: May 23, 2018, 8:00 a.m. to 5:15 p.m. Agenda: To review and evaluate grant
Center for Scientific Review; Notice of
Agenda: To review and evaluate program applications.
Place: National Institutes of Health, Closed Meetings
documents.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Pursuant to section 10(d) of the
Building 31, Room: 4C32, 31 Center Drive, Boulevard, Rockville, MD 20852 (Telephone
Federal Advisory Committee Act, as
Bethesda, MD 20892. Conference Call).
Contact Person: Susan O. McGuire, Ph.D., amended, notice is hereby given of the
Contact Person: John J. O’Shea, MD, Ph.D., following meetings.
Scientific Director, National Institute of Scientific Review Officer, Office of
Extramural Policy and Review, National The meetings will be closed to the
Arthritis & Musculoskeletal and Skin public in accordance with the
Institute on Drug Abuse, National Institutes
Diseases, Building 10, Room 9N228, MSC
of Health, DHHS, 6001 Executive Blvd., provisions set forth in sections
1820, Bethesda, MD 20892, (301) 496–2612,
Room 4245, Rockville, MD 20852, (301) 827– 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
osheaj@arb.niams.nih.gov.
5817, mcguireso@mail.nih.gov. as amended. The grant applications and
Any interested person may file written This notice is being published less than 15
comments with the committee by forwarding
the discussions could disclose
days prior to the meeting due to the timing confidential trade secrets or commercial
the statement to the Contact Person listed on limitations imposed by the review and
this notice. The statement should include the property such as patentable material,
funding cycle. and personal information concerning
name, address, telephone number and when
applicable, the business or professional Name of Committee: National Institute on individuals associated with the grant
Drug Abuse Special Emphasis Panel; BRAIN applications, the disclosure of which
affiliation of the interested person.
Initiative: Tools to Target, Identify and
In the interest of security, NIH has would constitute a clearly unwarranted
Characterize Non-Neuronal Cells in the Brain
instituted stringent procedures for entrance invasion of personal privacy.
(R01).
onto the NIH campus. All visitor vehicles,
Date: May 11, 2018. Name of Committee: Center for Scientific
including taxicabs, hotel, and airport shuttles Time: 11:00 a.m. to 4:00 p.m. Review Special Emphasis Panel; RFA–CA–
will be inspected before being allowed on Agenda: To review and evaluate grant 17–035—Pre-Cancer Atlas Research Centers.
campus. Visitors will be asked to show one applications. Date: May 17–18, 2018.
form of identification (for example, a
amozie on DSK30RV082PROD with NOTICES

Place: National Institutes of Health, Time: 8:00 a.m. to 6:00 p.m.
government-issued photo ID, driver’s license, Neuroscience Center, 6001 Executive Agenda: To review and evaluate grant
or passport) and to state the purpose of their Boulevard, Rockville, MD 20852 (Telephone applications.
visit. Conference Call). Place: Bethesda North Marriott Hotel &
(Catalogue of Federal Domestic Assistance Contact Person: Julia Berzhanskaya, Ph.D., Conference Center, 5701 Marinelli Road,
Program Nos. 93.846, Arthritis, Scientific Review Officer, Office of Bethesda, MD 20852.
Musculoskeletal and Skin Diseases Research, Extramural Policy and Review, Division of Contact Person: Lambratu Rahman Sesay,
National Institutes of Health, HHS) Extramural Research. National Institute on Ph.D., Scientific Review Officer, Center for

VerDate Sep<11>2014 17:09 Apr 20, 2018 Jkt 244001 PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 E:\FR\FM\23APN1.SGM 23APN1

Document Created: 2018-04-21 00:33:28
Document Modified: 2018-04-21 00:33:28

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		April 26, 2018.
FR Citation		83 FR 17668

83 FR 17668 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 78 (April 23, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health